Vivos Therapeutics, Inc.
VVOS
$0.53
-$0.04-7.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -98.81% | -143.86% | -106.30% | -159.88% | -2.68% |
| Total Depreciation and Amortization | 156.50% | 206.94% | 163.01% | 111.03% | 21.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 132.18% | -282.26% | -62.84% | 15.93% | 6.02% |
| Change in Net Operating Assets | 213.15% | 963.01% | 142.86% | 155.87% | -153.12% |
| Cash from Operations | -58.32% | -29.66% | 0.62% | -14.63% | -50.87% |
| Capital Expenditure | 85.25% | -827.88% | 143.23% | -1,185.00% | 19.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 85.25% | -858.18% | 143.23% | -9,743.33% | 19.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -19.97% | -23.32% | -64.60% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 121.75% | 80.94% | -737.00% | -- |
| Cash from Financing | -- | 41.94% | -27.04% | 54.86% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 102.07% | -1,974.51% | -122.13% | -52.00% | -504.75% |